Postpandemic Sentinel Surveillance of Respiratory Diseases in the Context of the World Health Organization Mosaic Framework: Protocol for a Development and Evaluation Study Involving the English Primary Care Network 2023-2024.
COVID-19
World Health Organization
computerized medical record system
human influenza
influenza vaccines
pandemic
phenotype
respiratory syncytial virus
respiratory tract infections
sentinel surveillance
vaccination
Journal
JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
received:
30
08
2023
accepted:
17
01
2024
revised:
02
01
2024
medline:
5
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
epublish
Résumé
Prepandemic sentinel surveillance focused on improved management of winter pressures, with influenza-like illness (ILI) being the key clinical indicator. The World Health Organization (WHO) global standards for influenza surveillance include monitoring acute respiratory infection (ARI) and ILI. The WHO's mosaic framework recommends that the surveillance strategies of countries include the virological monitoring of respiratory viruses with pandemic potential such as influenza. The Oxford-Royal College of General Practitioner Research and Surveillance Centre (RSC) in collaboration with the UK Health Security Agency (UKHSA) has provided sentinel surveillance since 1967, including virology since 1993. We aim to describe the RSC's plans for sentinel surveillance in the 2023-2024 season and evaluate these plans against the WHO mosaic framework. Our approach, which includes patient and public involvement, contributes to surveillance objectives across all 3 domains of the mosaic framework. We will generate an ARI phenotype to enable reporting of this indicator in addition to ILI. These data will support UKHSA's sentinel surveillance, including vaccine effectiveness and burden of disease studies. The panel of virology tests analyzed in UKHSA's reference laboratory will remain unchanged, with additional plans for point-of-care testing, pneumococcus testing, and asymptomatic screening. Our sampling framework for serological surveillance will provide greater representativeness and more samples from younger people. We will create a biomedical resource that enables linkage between clinical data held in the RSC and virology data, including sequencing data, held by the UKHSA. We describe the governance framework for the RSC. We are co-designing our communication about data sharing and sampling, contextualized by the mosaic framework, with national and general practice patient and public involvement groups. We present our ARI digital phenotype and the key data RSC network members are requested to include in computerized medical records. We will share data with the UKHSA to report vaccine effectiveness for COVID-19 and influenza, assess the disease burden of respiratory syncytial virus, and perform syndromic surveillance. Virological surveillance will include COVID-19, influenza, respiratory syncytial virus, and other common respiratory viruses. We plan to pilot point-of-care testing for group A streptococcus, urine tests for pneumococcus, and asymptomatic testing. We will integrate test requests and results with the laboratory-computerized medical record system. A biomedical resource will enable research linking clinical data to virology data. The legal basis for the RSC's pseudonymized data extract is The Health Service (Control of Patient Information) Regulations 2002, and all nonsurveillance uses require research ethics approval. The RSC extended its surveillance activities to meet more but not all of the mosaic framework's objectives. We have introduced an ARI indicator. We seek to expand our surveillance scope and could do more around transmissibility and the benefits and risks of nonvaccine therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Prepandemic sentinel surveillance focused on improved management of winter pressures, with influenza-like illness (ILI) being the key clinical indicator. The World Health Organization (WHO) global standards for influenza surveillance include monitoring acute respiratory infection (ARI) and ILI. The WHO's mosaic framework recommends that the surveillance strategies of countries include the virological monitoring of respiratory viruses with pandemic potential such as influenza. The Oxford-Royal College of General Practitioner Research and Surveillance Centre (RSC) in collaboration with the UK Health Security Agency (UKHSA) has provided sentinel surveillance since 1967, including virology since 1993.
OBJECTIVE
OBJECTIVE
We aim to describe the RSC's plans for sentinel surveillance in the 2023-2024 season and evaluate these plans against the WHO mosaic framework.
METHODS
METHODS
Our approach, which includes patient and public involvement, contributes to surveillance objectives across all 3 domains of the mosaic framework. We will generate an ARI phenotype to enable reporting of this indicator in addition to ILI. These data will support UKHSA's sentinel surveillance, including vaccine effectiveness and burden of disease studies. The panel of virology tests analyzed in UKHSA's reference laboratory will remain unchanged, with additional plans for point-of-care testing, pneumococcus testing, and asymptomatic screening. Our sampling framework for serological surveillance will provide greater representativeness and more samples from younger people. We will create a biomedical resource that enables linkage between clinical data held in the RSC and virology data, including sequencing data, held by the UKHSA. We describe the governance framework for the RSC.
RESULTS
RESULTS
We are co-designing our communication about data sharing and sampling, contextualized by the mosaic framework, with national and general practice patient and public involvement groups. We present our ARI digital phenotype and the key data RSC network members are requested to include in computerized medical records. We will share data with the UKHSA to report vaccine effectiveness for COVID-19 and influenza, assess the disease burden of respiratory syncytial virus, and perform syndromic surveillance. Virological surveillance will include COVID-19, influenza, respiratory syncytial virus, and other common respiratory viruses. We plan to pilot point-of-care testing for group A streptococcus, urine tests for pneumococcus, and asymptomatic testing. We will integrate test requests and results with the laboratory-computerized medical record system. A biomedical resource will enable research linking clinical data to virology data. The legal basis for the RSC's pseudonymized data extract is The Health Service (Control of Patient Information) Regulations 2002, and all nonsurveillance uses require research ethics approval.
CONCLUSIONS
CONCLUSIONS
The RSC extended its surveillance activities to meet more but not all of the mosaic framework's objectives. We have introduced an ARI indicator. We seek to expand our surveillance scope and could do more around transmissibility and the benefits and risks of nonvaccine therapies.
Identifiants
pubmed: 38569175
pii: v10i1e52047
doi: 10.2196/52047
pmc: PMC11024753
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e52047Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
©Xinchun Gu, Conall Watson, Utkarsh Agrawal, Heather Whitaker, William H. Elson, Sneha Anand, Ray Borrow, Anna Buckingham, Elizabeth Button, Lottie Curtis, Dominic Dunn, Alex J. Elliot, Filipa Ferreira, Rosalind Goudie, Uy Hoang, Katja Hoschler, Gavin Jamie, Debasish Kar, Beatrix Kele, Meredith Leston, Ezra Linley, Jack Macartney, Gemma L Marsden, Cecilia Okusi, Omid Parvizi, Catherine Quinot, Praveen Sebastianpillai, Vanashree Sexton, Gillian Smith, Timea Suli, Nicholas P B Thomas, Catherine Thompson, Daniel Todkill, Rashmi Wimalaratna, Matthew Inada-Kim, Nick Andrews, Victoria Tzortziou-Brown, Rachel Byford, Maria Zambon, Jamie Lopez-Bernal, Simon de Lusignan. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 03.04.2024.
Références
BMC Public Health. 2022 Jun 9;22(1):1151
pubmed: 35681199
Nat Genet. 2022 Apr;54(4):499-507
pubmed: 35347305
J Am Med Inform Assoc. 2022 Aug 16;29(9):1449-1460
pubmed: 35799370
Inform Prim Care. 2005;13(1):65-70
pubmed: 15949178
BMC Public Health. 2020 Nov 20;20(1):1748
pubmed: 33218318
Lancet Microbe. 2021 Sep;2(9):e481-e484
pubmed: 34337584
Cochrane Database Syst Rev. 2018 Feb 01;2:CD004879
pubmed: 29388195
J Antimicrob Chemother. 2022 Feb 23;77(3):803-806
pubmed: 35038341
Br J Gen Pract. 2017 Oct;67(663):440-441
pubmed: 28963401
Med Law Rev. 2015 Summer;23(3):348-74
pubmed: 25995294
Cochrane Database Syst Rev. 2018 Feb 01;2:CD008983
pubmed: 29388675
Thorax. 2018 Apr;73(4):313-320
pubmed: 29074814
Influenza Other Respir Viruses. 2018 Sep;12(5):551-557
pubmed: 29722140
JMIR Res Protoc. 2023 Jun 16;12:e46938
pubmed: 37327029
Stud Health Technol Inform. 2009;150:243-7
pubmed: 19745305
Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876
pubmed: 20166072
Epidemiology. 2020 Jan;31(1):43-64
pubmed: 31609860
Br J Gen Pract. 2020 Nov 26;70(701):e890-e898
pubmed: 33077508
Euro Surveill. 2022 Jun;27(26):
pubmed: 35775429
Epidemiol Infect. 2018 Jul;146(9):1106-1113
pubmed: 29743125
Commun Dis Rep CDR Rev. 1994 Dec 9;4(13):R164-8
pubmed: 7531565
Influenza Other Respir Viruses. 2015 Sep;9(5):234-46
pubmed: 26031655
JMIR Public Health Surveill. 2021 Feb 19;7(2):e24341
pubmed: 33605892
Clin Infect Dis. 2023 Mar 21;76(6):1030-1037
pubmed: 36327388
Euro Surveill. 2023 Jan;28(3):
pubmed: 36695484
Adv Ther. 2023 Apr;40(4):1601-1627
pubmed: 36790682
Cochrane Database Syst Rev. 2018 Feb 01;2:CD001269
pubmed: 29388196
Age Ageing. 2023 May 1;52(5):
pubmed: 37140052
J Infect. 2023 Oct;87(4):315-327
pubmed: 37579793
J Am Med Inform Assoc. 2021 Aug 13;28(9):2017-2026
pubmed: 34151978
Influenza Other Respir Viruses. 2023 Mar 21;17(3):e13122
pubmed: 36970570
Open Forum Infect Dis. 2020 Jul 03;7(7):ofaa268
pubmed: 33123614
BMJ. 2017 Aug 2;358:j3453
pubmed: 28768629
Diagn Progn Res. 2021 Feb 8;5(1):4
pubmed: 33557927
Hum Vaccin Immunother. 2012 Jan;8(1):21-8
pubmed: 22252007
Health Expect. 2017 Oct;20(5):826-835
pubmed: 28664563
PLoS One. 2021 Mar 11;16(3):e0248123
pubmed: 33705452
Vaccine. 2016 Oct 26;34(45):5393-5399
pubmed: 27646029
Br J Gen Pract. 2023 May 25;73(731):e435-e442
pubmed: 37130611
BMC Prim Care. 2022 Jul 14;23(1):173
pubmed: 35836123
JAMA Netw Open. 2021 Dec 1;4(12):e2137257
pubmed: 34905008
Euro Surveill. 2021 Mar;26(11):
pubmed: 33739255
Commun Dis Public Health. 1999 Jun;2(2):96-100
pubmed: 10402742
JMIR Public Health Surveill. 2022 Dec 19;8(12):e39141
pubmed: 36534462
Bull World Health Organ. 2018 Feb 1;96(2):122-128
pubmed: 29403115
BMC Public Health. 2020 Apr 5;20(1):445
pubmed: 32248812
J Public Health (Oxf). 2021 Jun 7;43(2):e153-e160
pubmed: 32009178
BMJ. 2021 May 19;373:n1262
pubmed: 34011495
Vaccine. 2020 Jan 29;38(5):1152-1159
pubmed: 31839465
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Br J Gen Pract. 2020 Jul 30;70(697):e555-e562
pubmed: 32661013
J Am Med Inform Assoc. 2019 Dec 1;26(12):1545-1559
pubmed: 31329239
Stud Health Technol Inform. 2018;247:151-155
pubmed: 29677941
Respir Med. 2018 Nov;144:1-6
pubmed: 30366578
Fam Pract. 2016 Aug;33(4):408-13
pubmed: 27230745
Lancet. 2022 Oct 15;400(10360):1305-1320
pubmed: 36244382
Online J Public Health Inform. 2021 Dec 24;13(3):E15
pubmed: 35082977
J Infect. 2021 Aug;83(2):228-236
pubmed: 34004222
Viruses. 2020 Jan 14;12(1):
pubmed: 31947696